Company profile
Esperion Therapeutics
Lipid-lowering therapeutics
Delisted (Nasdaq: ESPR): taken private by ARCHIMED, merger completed 2026-07-13 · USA
Assets
(3 total)
3Total Assets
3Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
Bempedoic acid(Nexletol) | Approved | Adenosine Triphosphate-Citrate Lyase Inhibitor · ATP citrate lyaseSmall molecule | Atherosclerotic Cardiovascular Disease |
| Approved | ATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe)Small molecule | Atherosclerotic Cardiovascular Disease | |
| Approved | Undisclosed / early pipeline | Atherosclerotic Cardiovascular Disease |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.